Archive for the ‘NeoStem Inc. NBS’ Category

NeoStem, Inc. (NBS) Receives Two-Year $1.2 Million NIH Grant for First Clinical Study of VSEL Technology in Humans

Tuesday, November 20th, 2012

NeoStem is a firm engaged in the fast growing cell therapy industry. This industry is expected to have a significant role in the future in the fight against chronic disease. The company’s contract development and manufacturing service business, Progenitor Cell Therapy LLC, supports the development of proprietary cell therapy products.

The company today announced that it has been awarded a two-year grant totaling $1,221,854 from the National Institute of Dental and Craniofacial Research, a division of the National Institute of Health (NIH). The grant was for “Repair of Bone Defects With Human Autologous Pluripotent Very Small Embryonic-Like Stem Cells (VSEL)”. NeoStem has an exclusive worldwide license to VSEL technology.

This peer-reviewed grant will support a Phase II investigation and the first approved NIH clinical study of VSELs. The study, headed by Neostem’s Dennis O. Rodgerson, Ph.D., will be conducted in collaboration with Drs. Russell Taichman and Laurie McCauley of the University of Michigan. Enrollment of the study is expected to begin in 2013.

The study revolves around the evaluation of VSEL stem cells as a potential treatment for periodontitus. This disease affects up to 90% of the world’s population. The most severe form of periodontitus affects between 5% and 15% of the U.S. population. NeoStem’s product candidate is an autologous therapy derived from a patient’s own stem cells. Its aim is the regeneration of bone tissue damaged by severe periodontitus disease.

The market NeoStem’s therapy will be addressing is believed to generate $1.25-$1.5 billion annually. For additional information about NeoStem and VSEL technology, please visit www.neostem.com.

Let us hear your thoughts below:

NeoStem, Inc. (NBS) Ranked #1 in Tri-State Region

Thursday, November 15th, 2012

NeoStem today announced that the company has been ranked #1 regionally in the New York Tri-State region and #7 nationally on Deloitte’s 2012 Technology Fast 500. The ranking is a list of the 500 fastest growing technology, media, telecommunications, life sciences, and clean technology companies in North America.

Based in New York, NeoStem is focused on developing cell therapy products, technologies, and procedures. Through its subsidiary Progenitor Cell Therapy, the company is collaborating with Becton-Dickinson in the early clinical exploration of a T-cell therapy for autoimmune conditions. NeoStem’s most clinically advanced therapeutic product candidate, AMR-001, is being developed at Amorcyte, LLC, which was acquired by the company in 2011.

NeoStem’s business strategy combines a contract development and manufacturing organization (CDMO) with a medically important cell therapy product development program providing for near- and long-term revenue growth opportunities. The products developed this way are focused on markets for medical products centered around industries such as cardiovascular disease, autoimmune disorders, and regenerative medicine.

Dr. Robin L. Smith, NeoStem’s chairman and CEO, said, “We are proud to be recognized for this achievement as we build NeoStem into a top tier biopharmaceutical company and thrilled to be honored alongside such fast-growing, successful companies such as Celgene, LinkedIn, and Google. On behalf of the entire NeoStem team, I would like to thank Deloitte & Touche, LLP for their recognition of our efforts.”

For more information on NeoStem, visit www.neostem.com

Let us hear your thoughts below:

Small Cap Voice Featured Client: NeoStem, Inc. (AMEX: NBS)

Wednesday, November 14th, 2007

NeoStem, Inc. (AMEX: NBS) is focused on the delivery of adult stem cell therapeutics to consumers concerned about their health. The Company is currently developing a nationwide network of adult stem cell collection centers that enable people to store their own unique stem cells for personal use later on if critical medical needs arise.

Currently hundreds of stem cell-based research programs and clinical trials are investigating the uses of these non-controversial adult stem cells. NeoStem has positioned itself as a leader in the national trend toward protecting one’s future health as the United States’ population continues to encounter serious health issues.

The Company’s business plan is a service model that is highly-scalable, consequently minimizing risks usually associated with most long-term biopharmaceutical research and development. Under its strategic business plan, NeoStem’s stem cell collection systems will be located in existing physician offices and medical facilities where professional care can be administered by trusted personal doctors and medical professionals.

Let us hear your thoughts: NeoStem, Inc. (AMEX: NBS)

NeoStem (NBS) CEO Robin Smith to Ring Opening Bell at American Stock Exchange

Tuesday, October 23rd, 2007

NeoStem, Inc. (AMEX:NBS), a leading-edge healthcare company that seeks to capitalize on existing stem cell therapy applications, has announced that the company’s CEO Robin Smith, MD, will ring the opening bell at the American Stock Exchange on October 23rd, 2007.

Dr. Smith commented, “On behalf of all the employees and stockholders of NeoStem I am very gratified to take part in one of our financial community’s longest-standing traditions. NeoStem’s recent listing on the American Stock Exchange was an important milestone for us and we are excited to join the ranks of so many successful companies. We look forward to broadening our exposure within this great community of investors and to continue our work to build shareholder value as part of Amex.”

Let us hear your thoughts:

NeoStem, Inc’s (NBS) Video Details Promise of Current Adult Stem Cell Clinical Trials Targeting Widespread Diseases

Friday, October 19th, 2007

NeoStem, Inc. (NBS), a leading-edge healthcare company that intends to capitalize on existing stem cell applications, has released an investor video detailing the promise of adult stem cells.

Currently, clinical trials are underway to treat many of the world’s most intractable diseases through stem cell therapy. In fact, this industry is so prevalent that analysts predict that the adult stem cell industry will generate approximately $8.5 billion in revenue by 2016.

Robin Smith, MD, MBA, Chief Executive Officer of NeoStem, also details why the Company’s services should play a key role as the field of Regenerative Medicine fulfills the promise that many medical and scientific professionals anticipate.

“In the United States alone, there are nearly 700 ongoing studies currently underway to develop medical therapies based on adult stem cells, with nearly 200 of them focused on autologous applications,” said Dr. Smith during the video. “NeoStem believes there will be an overall growth in the adult stem cell industry, and it will be well positioned to capitalize on this growth.”

To view “The Promise of Stem Cells” investor video, please visit http://www.trilogy-capital.com/tcp/neostem

Let us hear your thoughts below:

SmallCapVoice Client: Neostem Inc. (NBS)

Monday, January 1st, 2007
 
NeoStem is a biotechnology services company enhancing the delivery of adult stem cell therapeutics to health-conscious consumers. The Company is developing a nationwide network of adult stem cell collection centers, enabling people to donate and store their own stem cells with NeoStem for personal use years or decades later in times of critical medical need. Although adult stem cell therapies are generally not standard of care, the Company believes medicine is on the threshold of a plethora of such new therapies.

The proprietary NeoStem technologies empower health-conscious consumers to help protect their future health by undergoing treatment with their own stem cells – providing an accessible supply of healthy, genetically matched stem cells for use in the eventuality of illness.

Currently underway are hundreds of stem cell-based research programs and clinical trials investigating the use of these non-controversial adult stem cells, such as those collected from donors under NeoStem’s methods. As the nation’s population ages and encounters serious age-related and congenital health issues, NeoStem has positioned itself as a leader in the national trend toward protecting one’s future health.

The Company’s business plan is a service model that is completely scalable, thus minimizing risk levels ordinarily related to most long-term biopharmaceutical research and development. Under its strategic business plan, NeoStem has begun opening a nationwide network of adult stem cell collection facilities. Its stem cell collection systems will be located in existing physician offices and medical facilities, where the procedures and care can be administered by trusted personal doctors and medical professionals.

For more information, please visit: http://www.qualitystocks.net/partners.php?partnerid=scvoice”